What happened
Samsung Biologics updated the disclosed terms of a subsidiary's acquisition of PolyPeptide Group AG, now worth US$2.01B.
For context, this deal is worth about 24.5% of the company's consolidated total assets.
| Target | PolyPeptide Group AG |
|---|---|
| Deal value | US$2.01B |
| vs. company assets | 24.5% |
| Filed | 2026-10-16, [Amended] Decision to acquire shares/equity in another company (subsidiary) |
| Source | DART rcept 20261016800441 → open original filing |
Versions of this filing
- 2026-08-31Original
- 2026-10-16Amendment 1 (this page)
Source: DART. Information only, not investment advice.